Clinical trials: Antidepressant
Major Depressive Disorder
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
This is a Phase 3 study designed to evaluate the safety and tolerability of two titration schedules for ALKS 5461.
- Trial name
- NCT02085135
- Testing
- ALKS 5461
- Where
- 9 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Alkermes, Inc.
Major Depressive Disorder, Depression, Unipolar
Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence
The purpose of this pilot study is to determine if taking a low dose of naltrexone in addition to an antidepressant medication can help treat relapse or recurrence in people with Major Depressive Disorder (MDD). The U.S.
- Conditions
- Major Depressive Disorder, Depression, Unipolar, Recurrence, Relapse
- Trial name
- NCT01874951
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
VA Augmentation and Switching Treatments for Improving Depression Outcomes
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments.
- Trial name
- VAST-D (NCT01421342)
- Testing
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Where
- 35 sites in United States
- Volunteers
- 1,522 people
- Sponsor
- VA Office of Research and Development
PTSD
Aripiprazole Augmentation of Antidepressants in PTSD
The proposed investigation will determine the therapeutic potential of aripiprazole augmentation to a stable antidepressant regimen for reducing posttraumatic stress disorder (PTSD) symptoms, cognitive symptoms, psychotic…
- Trial name
- NCT00489866
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Durham VA Medical Center
Major Depressive Disorder
Study of Neural Responses Induced by Antidepressant Effects
The proposed work aims to examine the neural changes associated with fast-acting antidepressant treatments in order to develop imaging-based biomarkers of treatment response for depression.
- Trial name
- SONRISA (NCT02674529)
- Testing
- Escitalopram, Real-time Neurofeedback fMRI task pre- and post-RCT
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Marta Peciña, MD PhD
Depression, Major Depressive Disorder
Flavanol Augmentation for Antidepressant Non-Responsive Late Life Depression
The goal of this proposal is to conduct the first pilot study of whether consuming flavanol supplements will augment the cognitive and mood benefits of antidepressant medication in older adults with Late LifeDepression (LLD).
- Trial name
- Flavanol (NCT02943096)
- Testing
- CocoaVia
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- New York State Psychiatric Institute
Depression
Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression
This study will evaluate the effectiveness of adding motivational interviewing to antidepressant treatment for major depressive disorder in Hispanic adults.
- Trial name
- NCT00564278
- Testing
- Standard antidepressant therapy (SADT), Motivational antidepressant therapy (MADT)
- Where
- United States
- Volunteers
- 217 people
- Sponsor
- New York State Psychiatric Institute
Unipolar Depression, Bipolar Depression
The Antidepressant Efficacy of the Anticholinergic Scopolamine
A previous study showed that the intravenous administration of scopolamine produces antidepressant effects. This study is designed to determine if other routes of administration of scopolamine produce antidepressant effects.
- Trial name
- NCT00369915
- Testing
- Scopolamine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD)
To demonstrate that the antidepressant activity of ETS6103 is not inferior to amitriptyline in subjects who have an unsatisfactory response to / are resistant to treatment with SSRIs.
- Trial name
- ETS6103-003 (NCT02014363)
- Testing
- ETS6103 (low dose), ETS6103 (high dose), Amitriptyline
- Where
- United Kingdom
- Volunteers
- 164 people
- Sponsor
- e-Therapeutics PLC
Major Depressive Disorder, Dysthymia
Project to Improve Symptoms and Mood in People With Spinal Cord Injury
Depression is likely the most prevalent and disabling psychological complication associated with spinal cord injury (SCI). Yet no controlled depression treatment trials have been performed in this population.
- Conditions
- Major Depressive Disorder, Dysthymia, Spinal Cord Injuries
- Trial name
- PRISMS (NCT00592384)
- Testing
- venlafaxine XR
- Where
- 6 sites in United States
- Volunteers
- 133 people
- Sponsor
- University of Washington
Major Depressive Disorder
A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder
The purpose of this study is to evaluate the safety, tolerability, and efficacy of TS-121 as an adjunctive treatment for patients with major depressive disorder with an inadequate response to current antidepressant Treatment…
- Trial name
- NCT03093025
- Testing
- TS-121 10 mg, TS-121 50 mg
- Where
- 22 sites in United States
- Volunteers
- 51 people
- Sponsor
- Taisho Pharmaceutical R&D Inc.
Adjunctive Treatment of Major Depressive Disorder
Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
To assess the safety and tolerability of long-term pimavanserin treatment in subjects with major depressive disorder and inadequate response to antidepressant treatment.
- Trial name
- NCT04000009
- Testing
- Pimavanserin
- Where
- 71 sites in United States, Finland and 7 more
- Volunteers
- 235 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Anxiety
An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants
This study is designed to evaluate anxious patients who are only partially responsive to typical SSRI or SNRI anti-anxiety medication therapy.
- Trial name
- NCT00591565
- Testing
- Acamprosate
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University
Depression, Mood Disorders
Rapid Antidepressant Effects of Ketamine in Major Depression
Depressive disorders may be severe, chronic and often life-threatening illnesses. Impairment in physical and social functioning resulting from depression can be just as severe as other chronic medical illnesses.
- Conditions
- Depression, Mood Disorders, Major Depresssion
- Trial name
- NCT00088699
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Depressive Disorder, Major
A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
The primary purpose is to study the efficacy, safety, and tolerability of LY2216684 as an adjunctive treatment for participants with major depressive disorder (MDD), who were identified as partial responders to an adequate course…
- Trial name
- NCT00840034
- Testing
- LY2216684
- Where
- 24 sites in United States
- Volunteers
- 227 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with…
- Trial name
- VENTURA-1 (NCT05455684)
- Testing
- Aticaprant
- Where
- 120 sites in United States, Argentina and 11 more
- Volunteers
- 513 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine
A 6-cohort single ascending dose (SAD) study will be conducted in healthy volunteers utilizing a slow-infusion intravenous (IV) route of administration.
- Trial name
- NCT04711005
- Testing
- (2R,6R)-Hydroxynorketamine hydrochloride
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
This study is looking at the efficacy, durability, safety, and tolerability of multiple single doses of Ketamine vs. active placebo for treating patients with treatment resistant depression who are taking an antidepressant that…
- Trial name
- NCT01920555
- Testing
- Ketamine
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
To evaluate the long-term efficacy and safety of brexpiprazole as an adjunctive treatment to an antidepressant treatment (ADT) for adult patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01838681
- Testing
- Brexpiprazole, ADT
- Where
- 107 sites in United States, Bulgaria and 14 more
- Volunteers
- 1,986 people
- Sponsor
- H. Lundbeck A/S
Depression
Augmenting Antidepressant Treatment With Interpersonal Psychotherapy for Treating Late-life Depression
This study will determine whether adding interpersonal psychotherapy to treatment with the antidepressant escitalopram will be more effective in reducing symptoms of depression than antidepressant medication alone.
- Trial name
- NCT00177294
- Testing
- Escitalopram, Interpersonal Psychotherapy, Clinical Monitoring
- Where
- United States
- Volunteers
- 319 people
- Sponsor
- University of Pittsburgh